Important Notice for Neumora Therapeutics, Inc. (NMRA) Shareholders
New York, NY, March 17, 2025:
The Gross Law Firm is notifying the shareholders of Neumora Therapeutics, Inc. (NMRA) that the firm is investigating potential securities fraud claims against the company. This investigation stems from allegations that Neumora may have made false and misleading statements to the public during the class period, which is currently believed to be from January 1, 2023, to December 31, 2024.
Class Period and Eligibility
The potential class action concerns Neumora’s alleged misrepresentation of its financial condition and business prospects. Shareholders who purchased or otherwise acquired the company’s securities during the class period are encouraged to contact the firm to discuss their potential role as a lead plaintiff in this action. The lead plaintiff is the representative party acting on behalf of the class in a securities class action.
Background
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing cannabinoid therapeutics for the treatment of various diseases and conditions. The company’s lead product candidate, NM-001, is a cannabidiol (CBD) oral solution for the treatment of post-traumatic stress disorder (PTSD).
Allegations
The Gross Law Firm’s investigation has revealed that Neumora may have issued materially false and misleading statements regarding its financial condition and business prospects. Specifically, it is alleged that the company downplayed the risks associated with its clinical trials and overstated the potential commercial success of NM-001.
Investors Affected
Shareholders who purchased or otherwise acquired Neumora securities during the class period may be able to recover their losses through a securities class action. The investigation is ongoing, and the firm encourages shareholders to contact it to discuss their potential role in the action.
Impact on Individual Investors
If Neumora is found to have engaged in securities fraud, individual investors who purchased the company’s securities during the class period may be able to recover their losses. Damages may include the difference between the purchase price and the value of the securities when the truth was revealed, as well as any related expenses and interest.
Impact on the World
The potential securities fraud allegations against Neumora Therapeutics could have far-reaching consequences. If the allegations are proven true, it could lead to increased scrutiny of the biotechnology industry and its regulatory bodies. It may also deter investors from investing in biotech companies, potentially slowing the pace of innovation in this sector.
Conclusion
The Gross Law Firm is committed to helping shareholders recover their losses when companies violate federal securities laws. If you purchased Neumora Therapeutics securities during the class period, you may be able to join this action and help hold the company accountable for any misrepresentations. For more information, please contact the firm as soon as possible.
- The Gross Law Firm is investigating potential securities fraud claims against Neumora Therapeutics, Inc.
- The alleged misrepresentations occurred during the class period from January 1, 2023, to December 31, 2024.
- Shareholders who purchased Neumora securities during the class period may be able to recover their losses.
- The investigation is ongoing, and shareholders are encouraged to contact the firm for more information.
- Damages may include the difference between the purchase price and the value of the securities when the truth was revealed, as well as any related expenses and interest.
- The potential consequences of the allegations could include increased scrutiny of the biotechnology industry and its regulatory bodies, as well as a deterrent to investment in this sector.
